ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
96,162.00
-1.35%
S&P 500
6,032.38
0.56%
Dow Jones
44,910.65
0.42%
US Dollar vs Yen
149.745
0.00%
Brent Oil
71.98
-0.08%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) ニュース

OKYO

OKYO Pharma (OKYO)

OKYO Pharma Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:OKYO
日付受信時刻ニュースソース見出しコード企業名
2024/11/2621 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/11/2621 : 00GlobeNewswire Inc.OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology ConferenceNASDAQ:OKYOOKYO Pharma Ltd
2024/10/3020 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/10/3020 : 00GlobeNewswire Inc.OKYO Pharma to Present at International Tear Film and Ocular Surface Society ConferenceNASDAQ:OKYOOKYO Pharma Ltd
2024/10/2320 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/10/2320 : 00GlobeNewswire Inc.OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
2024/10/1620 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/10/1620 : 00GlobeNewswire Inc.OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
2024/09/1020 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/09/1020 : 00GlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
2024/09/0520 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/09/0520 : 00GlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
2024/08/2720 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/08/2720 : 00GlobeNewswire Inc.OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
2024/08/2322 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/08/2322 : 00GlobeNewswire Inc.OKYO Pharma CEO Interview to Air on Bloomberg TVNASDAQ:OKYOOKYO Pharma Ltd
2024/08/2320 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/08/2320 : 00GlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
2024/08/2120 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/08/2120 : 00GlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
2024/08/1602 : 21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/08/1601 : 13GlobeNewswire Inc.OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:OKYOOKYO Pharma Ltd
2024/08/1405 : 30Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:OKYOOKYO Pharma Ltd
2024/08/0620 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/08/0620 : 00GlobeNewswire Inc.OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of UseNASDAQ:OKYOOKYO Pharma Ltd
2024/08/0106 : 00Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:OKYOOKYO Pharma Ltd
2024/07/1120 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/07/1120 : 00GlobeNewswire Inc.OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101NASDAQ:OKYOOKYO Pharma Ltd
2024/07/1020 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/07/1020 : 00GlobeNewswire Inc.OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:OKYO

最近閲覧した銘柄

NYSE
XOM
Exxon Mobil
FX
USDEUR
US Dollar vs Euro
COIN
XRPUSD
Ripple
COIN
AVAXUSD
Avalanche
NASDAQ
MSFT
Microsoft
FX
USDGBP
US Dollar vs Sterling
AMEX
XLE
Energy Select Sector SPDR
NYSE
MRK
Merck
CCOM
US100
US Tech 100
NYSE
MCD
McDonalds
NASDAQ
AAPL
Apple
SPI
SP500
S&P 500
NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
NASDAQ
AMZN
Amazon.com
NYSE
VZ
Verizon Communications
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有

BLACK FRIDAY

ADVFN

25周年を記念 1999-2024

Forexで最大60%オフ

1年間40％、2年間40％、*3年間60％

*3年間で¥ 153396、たったの¥ 61358